- Home
- SRPT vs HUMAW Comparison
SRPT vs HUMAW Comparison
Compare SRPT & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRPT | HUMAW |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | United States |
| Employees | N/A | 220 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | N/A |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRPT | HUMAW |
|---|---|---|
| Price | $20.42 | $0.10 |
| Analyst Decision | Hold | |
| Analyst Count | 29 | 0 |
| Target Price | ★ $26.23 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 14.2K |
| Earning Date | 11-03-2025 | 03-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,413,715,000.00 | N/A |
| Revenue This Year | $13.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.15 | N/A |
| 52 Week Low | $10.42 | $1.18 |
| 52 Week High | $129.84 | $1.34 |
Technical Indicators
Market Signals| Indicator | SRPT | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 36.06 |
| Support Level | $20.93 | $0.11 |
| Resistance Level | $22.97 | $0.15 |
| Average True Range (ATR) | 1.30 | 0.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 28.79 | 0.20 |
Price Performance
Historical ComparisonAbout SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.